Pfizer breast cancer prospect grabs FDA's speedy review promise

Pfizer's ($PFE) pipeline could use a big approval, and it may have one coming in palbociclib. The pharma giant has nabbed an FDA priority review designation for the closely watched cancer drug, which could potentially hack four months off the review timeline. Assuming approval, analysts see peak sales in the $3 billion range in Pfizer's future. More from FierceBiotech